Department of Otorhinolaryngology, Medical Faculty, Osmangazi University, Eskisehir, Turkey.
Eur Arch Otorhinolaryngol. 2010 May;267(5):725-30. doi: 10.1007/s00405-009-1159-5. Epub 2009 Nov 21.
Intranasal corticosteroids (INCSs) seem to be the best medication available to control and eliminate symptoms of allergic rhinitis. However, the amounts of nasal steroids prescribed and used were not directly proportional to the number of allergic rhinitis cases in Turkey. Herein, we aimed to clarify the unexpectedly low prescription and use of INCSs in Turkey by checking the outlook of patients' and physicians' perspectives. The patients' perspective on oral and nasal steroids was evaluated with a custom-designed questionnaire drawn up specifically for this preliminary study. The physicians' perspective on prescribing nasal steroids was evaluated with the data obtained from the IMS Health Turkey reports. The findings we obtained in this survey by analyzing data from the self-administered questionnaires showed that among these young people, oral and nasal steroids were on the whole well-known drugs. Hence, even though steroids in general are well-known drugs, the young people we surveyed mainly remained uninformed about their safety. The incidence of using nasal steroids if prescribed is higher than the one with oral steroids; that may be due to the lack of knowledge about nasal steroids. The analysis of the IMS Health Turkey data for nasal steroid prescriptions between 2005 and 2008 shows that the market share has increased steadily. The role of INCSs in the treatment of allergic rhinitis is increasingly being recognized as an appropriate and effective treatment option. However, patients' and parents' concerns over the safety of INCS therapy have frequently resulted in their being positioned as a second-line treatment choice. Physicians need to be aware that patients may have a significant information gap. Instructing the family and caregivers about the correct use of INCS therapy is an important part of treatment.
鼻内皮质类固醇（INCSs）似乎是控制和消除过敏性鼻炎症状的最佳药物。然而，在土耳其，鼻内类固醇的处方和使用量与过敏性鼻炎的病例数量不成正比。在此，我们旨在通过检查患者和医生的观点来阐明土耳其鼻内皮质类固醇处方和使用量异常低的原因。我们通过专门为此初步研究设计的定制问卷评估了患者对口服和鼻内皮质类固醇的看法。我们通过 IMS Health Turkey 报告中的数据评估了医生开鼻内皮质类固醇的看法。通过分析自我管理问卷中的数据，我们在这项调查中获得了调查结果，表明在这些年轻人中，口服和鼻内皮质类固醇总体上是广为人知的药物。因此，尽管皮质类固醇是众所周知的药物，但我们调查的年轻人主要对其安全性缺乏了解。如果开了处方，使用鼻内皮质类固醇的比例高于口服皮质类固醇；这可能是由于缺乏对鼻内皮质类固醇的了解。对 2005 年至 2008 年鼻内皮质类固醇处方的 IMS Health Turkey 数据分析表明，市场份额一直在稳步增长。INCS 在过敏性鼻炎治疗中的作用越来越被认为是一种合适且有效的治疗选择。然而，患者和家长对 INCS 治疗安全性的担忧经常导致其被定位为二线治疗选择。医生需要意识到患者可能存在重大信息差距。向患者家属和护理人员传授正确使用 INCS 治疗的知识是治疗的重要组成部分。
